Company news

Monopar Therapeutics Inc. news in 2026

Monopar Therapeutics Inc.'s news releases, calls and decks from 2026, newest first.

View company

Monopar to Present at AASLD – The Liver Meeting® 2026: Phase 3 FoCus Baseline Data and ALXN1840 Molybdenum Safety Data

November 2, 2026

Monopar Appoints Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs; Announces Two ALXN1840 Presentations at AASLD – The Liver Meeting® 2026

August 19, 2026

Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

August 13, 2026

Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

August 12, 2026

Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease

July 22, 2026

Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership Team

July 20, 2026

Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease

June 26, 2026

Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026

June 1, 2026

Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

May 14, 2026

Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026

April 19, 2026

Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update

March 27, 2026

Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer

March 1, 2026

Decks in 2026